ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2157

Dimensionality of Inflammatory Back Pain Criteria in the US Population

Mark Hwang1, Seokhun Kim2, Shervin Assassi3, Alexis Ogdie4, Michael Weisman5, John Reveille6 and Charles Green2, 1Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston, Houston, TX, 2UTHealth Houston, Houston, 3UTHealth Houston Division of Rheumatology, Houston, TX, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 5Stanford University, Los Angeles, CA, 6UTHealth Houston Division of Rheumatology, Houston

Meeting: ACR Convergence 2024

Keywords: Back pain, Patient reported outcomes, Psychometrics, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The evaluation of axial spondyloarthritis relies on capturing various inflammatory back pain (IBP) features, represented in IBP criteria. This study examines the dimensionality of various IBP criteria focusing on how many distinct constructs or dimensions they measure in a nationally representative sample.

Methods: We studied the National Health and Nutrition Examination Survey (NHANES) 2009-2010 dataset, a US nationally representative data collection with demographic weighting.  A one-time collection in NHANES contained the Arthritis Questionnaire (ARQ) in the 2009-2010 dataset, which included all questions from Calin, European Spondyloarthropathy Study Group (ESSG), and Berlin criteria (8a and 7b)(1).  Confirmatory Factor Analysis (CFA) was performed to assess if there are latent constructs underlying the observed items such as symptoms of back pain and stiffness and their dimensionality in the context of these criteria.  CFA models were assessed and compared using Chi-squared log-likelihood (LR) test (χ2) Comparative fit Index (CFI), Root Mean Square Error (RMSEA), and Standardized Root Mean Square Residual Aikike Information Criteria (AIC) and Bayesian Information Criteria (BIC) Exploratory Factor Analysis (EFA) was also conducted using the Principle Component Analysis (PCA) method with eigenvalues >1 and scree plot inflection points considered to determine optimal domains.

Results: There were 1511 patients with complete ARQ IBP questionnaires analyzed (Table 1).  For all IBP criteria (e.g., Calin, ESSG, Berlin 8a and Berlin 7b), CFA favored 1-factor models with non-significant chi-squared test, improved RMSEA, AIC and BIC observed as compared to 2-factor models.   However, there was potential multidimensionality observed on EFA in IBP questionnaires given the Scree plot inflection points of 3,3,1,1 factors for the Calin, ESSG, Berlin 8a and 7b questionnaires, respectively (Figure 1.).

Conclusion: This study demonstrates that IBP predominantly measure a single underlying construct, suggesting consistency in capturing a core aspect of axial spondyloarthritis. Despite some indications of multidimensionality in Exploratory Factor Analysis (EFA), the overall findings support the use of these criteria in clinical settings for a comprehensive patient assessment, particularly in the Berlin IBP criteria. Further research is needed to confirm the validity of these findings across different subpopulations on a national level.

Supporting image 1

Supporting image 2

Supporting image 3

Figure 1. Exploratory Factor Analysis Scree plots of Inflammatory Back Pain Criteria. The Berlin 8a (a.) and 7b (b.) had 1 factor identified via Principle Component Analysis and Promax rotation. .The Calin (c.) and ESSG (d.) IBP criteria had 3 factors identified.


Disclosures: M. Hwang: Eli Lilly, 5, Janssen, 5, UCB Pharma, 2; S. Kim: None; S. Assassi: AstraZeneca, 2, aTyr, 2, 5, BMS, 2, Boehringer-Ingelheim, 2, 5, CSL Behring, 2, Janssen, 5, Merck/MSD, 2, TeneoFour, 2; A. Ogdie: AbbVie, 2, 5, Amgen, 2, 5, Bristol Myers Squibb, 2, Celgene, 2, CorEvitas, LLC, 2, Eli Lilly and Company, 2, Gilead, 2, GSK, 2, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Takeda, 2, UCB Pharma, 2; M. Weisman: None; J. Reveille: None; C. Green: None.

To cite this abstract in AMA style:

Hwang M, Kim S, Assassi S, Ogdie A, Weisman M, Reveille J, Green C. Dimensionality of Inflammatory Back Pain Criteria in the US Population [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/dimensionality-of-inflammatory-back-pain-criteria-in-the-us-population/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dimensionality-of-inflammatory-back-pain-criteria-in-the-us-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology